INCHEON, Korea--(뉴스와이어)--Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed.

The release was issued prematurely by Samsung Bioepis Co., Ltd.

The news release will be updated and redistributed in the near future, incorporating further information on SB27.